Going concern warning clouds TrivarX’s Phase 1 ambitions

Funding uncertainty overshadows Stabl-Im pivot

TrivarX Limited (ASX:TRI) has placed a new brain-imaging platform at the centre of its strategy, but the annual report leaves little doubt about the financial pressure behind the pivot. The company recorded an $8.76 million net loss for FY2026, compared with $943,231 a year earlier, while auditor William Buck highlighted a material uncertainty that may cast significant doubt on the group’s ability to continue as a going concern.

The report says TrivarX expects to remain cash-flow negative as research and development continues and will need additional equity, debt or a combination of both to fund operations and technology development. Cash and cash equivalents stood at $2.44 million on 30 June 2026, while operating activities consumed $1.51 million during the year. Directors said expenditure can be managed for at least 12 months, but that assessment depends partly on further funding and expected government grants and tax incentives.

Stabl-Im becomes the lead development asset

The strategic answer is Stabl-Im, a stable isotope-enhanced MRI platform acquired in full from Nucleics during the December 2025 quarter. The technology uses controlled administration of deuterium oxide, with the aim of enabling MRI-based measurement of metabolic and proliferative activity. TrivarX says the approach could add biological information to conventional anatomical imaging, particularly when clinicians are trying to distinguish active tumour growth from treatment-related changes or radiation necrosis.

Stabl-Im was recognised as an intangible asset at $7.87 million and had a carrying value of $7.68 million at year-end after six months of amortisation. The company has appointed Beyond Drug Development to support the planned Phase 1 program, which is designed to begin with safety, tolerability and enrichment and washout kinetics in healthy volunteers. Subject to that initial component, an oncology expansion cohort is intended to assess preliminary imaging performance. Commencement is targeted for the second half of calendar 2026, subject to regulatory, ethics, site and operational requirements.

A large clinical and equity bill remains ahead

TrivarX raised $4.2 million through a placement priced at $0.008 a share, issuing 525 million new shares to institutional, sophisticated and professional investors. The funding supported the Stabl-Im acquisition and development program, as well as existing diagnostic projects and general working capital. Total ordinary shares on issue rose to 1.15 billion from 619.8 million a year earlier.

The acquisition also carries substantial potential dilution. The vendor received 750 million performance shares, with 250 million linked to a successful Phase 1 trial and 500 million linked to a successful Phase 2 trial within four years. A further 150 million facilitator options were issued at a $0.015 exercise price, with half tied to a successful Phase 1 outcome. The report also lists 381.1 million unlisted options on issue at 30 June, a sizeable overhang if the company’s development plans progress far enough to make those instruments valuable.

Mental health data moves to the sidelines

The company’s legacy mental health program produced encouraging, but early-stage, diagnostic results. In the US Department of Veterans Affairs study, 57 of 60 enrolled participants were included in the final analysis. The single-lead ECG algorithm recorded 97% sensitivity and 64% specificity for detecting current Major Depressive Episodes against clinician diagnosis, while the MEB-001 multi-biomarker algorithm recorded 88% sensitivity and 68% specificity.

TrivarX will maintain the relevant mental health intellectual property while prioritising potential partnering, licensing and other strategic opportunities. The financial statements show the cost of the transition: amortisation expenses reached $6.44 million and the company impaired a further $342,449 relating to its discontinued MLB Proof of Concept. The next decisive test is not another strategy statement, but whether TrivarX can fund and start the Stabl-Im study before its cash position becomes the constraint.